Latest news with #MohammadMahmoud
Medscape
20-05-2025
- Health
- Medscape
AUA 2025: Practice Impact of New mPC Data
Mohammad Mahmoud, MD, recalls how the AUA 2025 meeting in Las Vegas was an exciting and informative experience, especially regarding the management of metastatic prostate cancer. As a practicing urologist, Dr Mahmoud found the metastatic prostate cancer course particularly valuable for its practical updates on therapeutics like apalutamide and the importance of dose adjustments to reduce toxicity. He notes that the emphasis on genetic testing for patients with de novo metastatic disease and the emerging role of PARP inhibitors reinforced the need for personalized treatment approaches. Additionally, discussions around triplet therapy and the growing role of prostate-specific membrane antigen in both diagnostics and treatment are set to impact clinical decisions and tumor board discussions in meaningful ways.
Medscape
05-05-2025
- Health
- Medscape
AUA 2025: Key Highlights in Metastatic Prostate Cancer
Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising results from a novel BMS androgen receptor antagonist and degrader in heavily pretreated patients. New data also highlighted the risks of treatment interruption in castration-sensitive disease and emphasized the growing role of PARP inhibitors for BRCA1/2-mutated tumors. Dose adjustments of apalutamide were shown to reduce rash without compromising cancer control. Radiotherapeutics took the spotlight with Actinium-225-PSMA therapy showing effectiveness, including when combined with lutetium-177. Surgical studies like IP2-ATLANTA demonstrated the feasibility of cytoreductive treatments, while PSMA PET-guided metastasis-directed therapy showed potential for improving outcomes in patients with biochemical recurrence.
